Search Results: Treatment + BRCA + Prostate Cancer (12 results)
Testing a New Targeted Therapy ETX-19477 to Treat Advanced Solid Tumors (ERADIC8)
https://www.facingourrisk.org/research-clinical-trials/study/432 /testing-a-new-targeted-therapy-etx-19477-to-treat-advanced-solid-tumors-eradic8
Treatment
Phase 1/2 treatment study for people with advanced or metastatic cancer and a BRCA1 or BRCA2 mutation
Researchers are studying whether the targeted therapy ETX-19477 is a safe and effective treatment option for people with metastatic or advanced solid tumors. ETX-19477 is a type of drug known as a PARG inhibitor. It works by interfering with cancer cells' ability to repair damage to their DNA. Researchers hope this may slow tumor growth or cause cancer cells to die.The goal of this study is to find the safest and most effective dose of ETX-19477 for treating metastatic or advanced cancers. The study is currently enrolling people with a BRCA1 or BRCA2 mutation.
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone or Darolutamide (TALENT)
https://www.facingourrisk.org/research-clinical-trials/study/425 /a-study-of-talazoparib-with-or-without-enzalutamide-in-people-with-prostate-cancer-who-have-previously-received-abiraterone-or-darolutamide-talent
Treatment
Phase 2 study for metastatic castration-resistant prostate cancer with an HRR mutation
Phase 2 study comparing talazoparib with or without Enzalutamide in patients with metastatic castration-resistant prostate cancer and an HRR mutation after progression on Abiraterone Acetate or Darolutamide
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/300 /study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced solid tumors
The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations.
Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2
https://www.facingourrisk.org/research-clinical-trials/study/376 /using-a-parp-inhibitor-and-oral-chemotherapy-to-treat-advanced-solid-tumors-with-a-mutation-in-brca1-brca2-palb2-atm-or-chek2
Treatment
Phase 1 treatment study for metastatic solid tumors
This study is testing a new combination of two oral drugs to see if they are safe and show signs of helping people with advanced cancer whose tumors have mutations in one of these genes: BRCA1, BRCA2, PALB2, ATM, and CHEK2.
A Study of the PARP Inhibitor Saruparib Added to Standard Treatment for High Risk BRCA-Positive Prostate Cancer (EvoPAR PR02)
https://www.facingourrisk.org/research-clinical-trials/study/369 /a-study-of-the-parp-inhibitor-saruparib-added-to-standard-treatment-for-high-risk-brca1-positive-prostate-cancer
Treatment
Phase 3 treatment study for BRCA-positive high-risk prostate cancer
This study is testing a new medication called saruparib (AZD5305) to see if it can help people with prostate cancer that is high risk for getting worse or spreading to other parts of the body. Saruparib is a type of targeted therapy known as a PARP inhibitor. The study is open to people with a BRCA1 or BRCA2 mutation in their tumor. The goal of this study is to find out if adding saruparib after radiation treatment can lower the chances of the cancer coming back or spreading.
A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with an ATM, BRCA1/2, CHEK2, PALB2 or Other Mutation
https://www.facingourrisk.org/research-clinical-trials/study/377 /an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
This research study is testing the safety and effectiveness of an investigational targeted therapy called CX‑5461. The goal is to find a safe dose and learn more about how well the drug works to treat advanced breast, ovarian, pancreatic or prostate cancers in people with certain inherited or tumor‑related gene mutations, including ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, NBN, PALB2, RAD51C, RAD51D or other mutations related to DNA repair.
Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas
https://www.facingourrisk.org/research-clinical-trials/study/311 /study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
This study is looking at the safety and best dose for treatment with the drug ONM-501 alone or in combination with immunotherapy for treating advanced solid tumors or lymphomas.
Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
https://www.facingourrisk.org/research-clinical-trials/study/286 /swog-s2210-carboplatin-chemotherapy-before-surgery-for-patients-with-high-risk-prostate-cancer-and-an-inherited-brca1-or-brca2-gene-mutation
Treatment
Treatment before surgery for people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation
This study tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer who have inherited BRCA1 or BRCA2 gene mutations. The purpose of the study is to treat men with BRCA1 or BRCA2 mutations who are at higher risk of prostate cancer after surgery (removal of the prostate) compared to patients without these mutations.
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262 /tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Treatment
Cancer treatment study for people with advanced solid tumors
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Metastatic Castration Resistant Prostate Cancer Clinical Trial
https://www.facingourrisk.org/research-clinical-trials/study/240 /metastatic-castration-resistant-prostate-cancer-clinical-trial
Treatment
Treatment study for men with metastatic castration resistant prostate cancer
Metastatic prostate cancer that no longer responds to hormone therapy is called metastatic castration resistant prostate cancer (mCRPC). This clinical trial may be an option for you if you have been diagnosed with mCRPC that has spread or gotten worse since your last treatment. Participants will be randomly assigned to receive the current standard of care medicine, enzalutamide, or PF-06821497 (study medicine) orally in combination with enzalutamide.
Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)
https://www.facingourrisk.org/research-clinical-trials/study/210 /treating-metastatic-prostate-cancer-with-chemotherapy-or-parp-inhibitor-in-people-with-mutations-cobra
Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L
This study is comparing carboplatin chemotherapy to the drug, olaparib (a type of targeted therapy) as first-line treatment for metastatic castration-resistant prostate cancer in people with a BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L inherited mutation found through genetic testing, or tumor mutation found through biomarker testing.
Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/157 /treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Treatment
Phase 1/2 treatment study for advanced solid tumors
This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.
Additional Results on Clinicaltrials.gov Treatment + BRCA + Prostate Cancer
2 results
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT ID: NCT05806515 (https://clinicaltrials.gov/study/NCT05806515)
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
NCT ID: NCT04038502 (https://clinicaltrials.gov/study/NCT04038502)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.